Combined vector vaccine for the prevention of coronavirus infection caused by the SARS-CoV-2 virus.
The Gam-COVID-Vac vaccine was developed by the Federal State Budgetary Institution N.F. Gamaleya Federal Research Centre for Epidemiology and Microbiology of the Ministry of Health of the Russian Federation and became world's first registered vaccine for the prevention of coronavirus infection COVID‑19. The vaccine is based on an adenovirus vector with inserted built-in genetic material fragment SARS-COV-2, which codes information about the structure of the spike S protein (which forms the virus' 'crown', responsible for its binding to human cells).The fragment of genetic material itself is safe for humans, but at the same time it is able to ensure the formation of a robust antibody and cellular immune response to the virus.
Scaling-up of the vaccine production technology at the GENERIUM manufacturing site was performed using modern process approaches and advanced equipment. A wide team of GENERIUM specialists with many years of experience in the development and production of biotechnological medicinal products is involved in this project.
GENERIUM is the first company that has completed the transfer of the full cycle of vaccine production: from the substance to the finished form.